Neurocrine Biosciences (NBIX) Other Operating Expenses (2010 - 2026)

Neurocrine Biosciences has reported Other Operating Expenses for 16 years, with the latest figure at $28.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $28.6 million; the trailing twelve-month figure through Mar 2026 stood at $318.1 million (up 46.86% YoY), and the FY2025 full-year result was $69.5 million, up 49.46% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $28.6 million, down from $34.6 million in the prior quarter.
• The five-year high for Other Operating Expenses was $240.6 million in Q2 2025, with the low at $6.1 million in Q3 2022.
• Historically, Other Operating Expenses has averaged $69.4 million across 5 years, with a median of $21.4 million in 2025.
• The largest YoY upside for Other Operating Expenses was 3331.03% in 2022 against a maximum downside of 93.33% in 2022.
• Neurocrine Biosciences' Other Operating Expenses stood at $7.7 million in 2022, then increased by 10.39% to $8.5 million in 2023, then soared by 44.71% to $12.3 million in 2024, then jumped by 181.3% to $34.6 million in 2025, then declined by 17.34% to $28.6 million in 2026.
• The last three Other Operating Expenses figures came in at $28.6 million (Q1 2026), $34.6 million (Q4 2025), and $14.3 million (Q3 2025), per Business Quant data.